Publications

Research Publications, Peer Reviewed

  1. Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol. 2001; 166(11):6812-9.
  2. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology. 2001; 34(1):89-100.
  3. Schnabl B, Bradham CA, Bennett BL, Manning AM, Stefanovic B, Brenner DA. TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. Hepatology. 2001; 34(5):953-63.
  4. Schnabl B, Choi YH, Olsen JC, Hagedorn CH, Brenner DA. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest. 2002; 82(3):323-33.
  5. Stefanovic B, Schnabl B, Brenner DA. Inhibition of collagen alpha 1(I) expression by the 5' stem-loop as a molecular decoy. J Biol Chem. 2002; 277(20):18229-37.
  6. Schnabl B, Purbeck CA, Choi YH, Hagedorn CH, Brenner D. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology. 2003; 37(3):653-64.
  7. Kweon YO, Paik YH, Schnabl B, Qian T, Lemasters JJ, Brenner DA. Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J Hepatol. 2003; 39(1):38-46.
  8. Stefanovic B, Stefanovic L, Schnabl B, Bataller R, Brenner DA. TRAM2 protein interacts with endoplasmic reticulum Ca2+ pump Serca2b and is necessary for collagen type I synthesis. Mol Cell Biol. 2004; 24(4):1758-68.
  9. Mühlbauer M, Weiss TS, Thasler WE, Gelbmann CM, Schnabl B, Schölmerich J, Hellerbrand C. LPS-mediated NFkappaB activation varies between activated human hepatic stellate cells from different donors. Biochem Biophys Res Commun. 2004; 325(1):191-7.
  10. Schnabl B, Choi YH, Hagedorn CH, Bataller R. DNA microarrays and data mining to study hepatic fibrosis. Methods Mol Med. 2005; 117:359-69.
  11. Hu K, Fink M, Froh M, Gäbele E, Hellerbrand C, Mühlbauer M, Wiest R, Schölmerich J, Schnabl B. Characterization of the human zinc finger protein 267 promoter: essential role of nuclear factor Y. Biochim Biophys Acta. 2005; 1729(1):14-23.
  12. Schnabl B, Hu K, Mühlbauer M, Hellerbrand C, Stefanovic B, Brenner DA, Schölmerich J. Zinc finger protein 267 is up-regulated during the activation process of human hepatic stellate cells and functions as a negative transcriptional regulator of MMP-10. Biochem Biophys Res Commun. 2005; 335(1):87-96.
  13. Meiler C, Muhlbauer M, Johann M, Hartmann A, Schnabl B, Wodarz N, Schmitz G, Scholmerich J, Hellerbrand C. Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J Gastroenterol. 2005; 11(38):6031-7.
  14. Wiest R, Jurzik L, Moleda L, Froh M, Schnabl B, von Hörsten S, Schölmerich J, Straub RH. Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. J Hepatol. 2006; 44(3):512-9.
  15. Tacke F, Trautwein C, Yagmur E, Hellerbrand C, Wiest R, Brenner DA, Schnabl B. Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol. 2007; 22(8):1256-64.
  16. Brandl K, Plitas G, Schnabl B, DeMatteo RP, Pamer EG. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med. 2007; 204(8):1891-900.
  17. Tacke F, Gäbele E, Bataille F, Schwabe RF, Hellerbrand C, Klebl F, Straub RH, Luedde T, Manns MP, Trautwein C, Brenner DA, Schölmerich J, Schnabl B. Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci. 2007; 52(12):3404-15.
  18. Brandl K, Plitas G, Mihu CN, Ubeda C, Jia T, Fleisher M, Schnabl B, DeMatteo RP, Pamer EG. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature. 2008; 455(7214):804-7.
  19. Schnabl B, Brandl K, Fink M, Gross P, Taura K, Gäbele E, Hellerbrand C, Falk W. A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun. 2008; 375(2):210-4.
  20. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008; 48(5):1420-9.
  21. Gäbele E, Mühlbauer M, Dorn C, Weiss TS, Froh M, Schnabl B, Wiest R, Schölmerich J, Obermeier F, Hellerbrand C. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun. 2008; 376(2):271-6.
  22. De Minicis S, Seki E, Oesterreicher C, Schnabl B, Schwabe RF, Brenner DA. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology. 2008; 48(6):2016-26.
  23. Brandl K, Rutschmann S, Li X, Du X, Xiao N, Schnabl B, Brenner DA, Beutler B. Enhanced sensitivity to DSS colitis caused by a hypomorphic Mbtps1 mutation disrupting the ATF6-driven unfolded protein response. Proc Natl Acad Sci U S A. 2009; 106(9):3300-5.
  24. Kodama Y, Taura K, Miura K, Schnabl B, Osawa Y, Brenner DA. Antiapoptotic Effect of c-Jun N-terminal Kinase-1 through Mcl-1 Stabilization in TNF-induced Hepatocyte Apoptosis. Gastroenterology. 2009; 136(4):1423-34.
  25. Kodama Y, Kisseleva T, Iwaisako K, Miura K, Taura K, De Minicis S, Österreicher CH, Schnabl B, Seki E, Brenner DA. JNK1 Derived from Hematopoietic Cells Mediates Progression from Diet-Induced Hepatic Steatosis to Steatohepatitis and Fibrosis in Mice. Gastroenterology. 2009; 137(4):1467-1477.
  26. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA, Seki E. Toll-like receptor 9 promotes steatohepatitis via induction of interleukin-1β in mice. Gastroenterology. 2010; 139(1):323-34.
  27. Tacke F, Zimmermann HW, Trautwein C, Schnabl B. CXCL5 plasma levels are decreased in patients with chronic liver disease. J Gastroenterol Hepatol. 2011; 26(3):523-9.
  28. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B. Enteric Dysbiosis Associated with a Mouse Model of Alcoholic Liver Disease. Hepatology. 2011; 53(1):96-105.
  29. Paik YH, Iwaisako K, Seki E, Inokuchi S, Schnabl B, Osterreicher CH, Kisseleva T, Brenner DA. The nicotinamide adenine dinucleotide phosphate oxidase homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. Hepatology 2011; 53(5):1730-41.
  30. Siggs OM, Schnabl B, Webb B, Beutler B. X-linked cholestasis in mouse due to mutations of the P4-ATPase ATP11C. Proc Natl Acad Sci U S A. 2011; 108(19):7890-5.
  31. Schnabl B, Valletta D, Kirovski G, Hellerbrand C. Zinc finger protein 267 is up-regulated in hepatocellular carcinoma and promotes tumor cell proliferation and migration. Exp Mol Pathol. 2011; 91(3):695-701.
  32. Schnabl B, Czech B, Valletta D, Weiss TS, Kirovski G, Hellerbrand C. Increased expression of Zinc finger protein 267 in non-alcoholic fatty liver disease. Int J Clin Exp Pathol. 2011; 4(7):661-6.
  33. Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol. 2012; 56:1283–92.
  34. Iwaisako K, Haimerl M, Paik YH, Taura K, Kodama Y, Sirlin C, Yu E, Yu RT, Downes M, Evans RM, Brenner DA, Schnabl B. Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc Natl Acad Sci U S A. 2012; 109(21):E1369-76.
  35. Brandl K, Tomisato W, Li X, Neppl C, Pirie E, Falk W, Xia Y, Moresco EY, Baccala R, Theofilopoulos AN, Schnabl B, Beutler B. Yip1 domain family, member 6 (Yipf6) mutation induces spontaneous intestinal inflammation in mice. Proc Natl Acad Sci U S A. 2012;109(31):12650-5.
  36. Hartmann P, Haimerl M, Mazagova M, Brenner DA, Schnabl B. Toll-Like Receptor 2-mediated intestinal injury and enteric Tumor Necrosis Factor Receptor I contribute to liver fibrosis in mice. Gastroenterology. 2012; 143(5):1330-1340.
  37. Grivennikov S, Wang K, Mucida D, Stewart AC, Schnabl B, Jauch D, Taniguchi K, Yu G, Osterreicher C, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M. Adenoma-associated barrier deterioration drives IL-23 dependent inflammation and tumor growth. Nature. 2012; 491(7423):254-8.
  38. Hartmann P, Chen P, Wang HJ, Wang L, McCole DF, Brandl K, Stärkel P, Belzer C, Hellerbrand C, Tsukamoto H, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology 2013; 58(1):108-19.
  39. Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, Seki E, Sirlin CB, Loomba R. Insulin resistance increases MRI-estimated pancreatic fat in nonalcoholic fatty liver disease and normal controls. Gastroenterology Research and Practice. 2013; 2013:498296.
  40. Wang L, Hartmann P, Haimerl M, Bathena SP, Sjöwall C, Almer S, Alnouti Y, Hofmann AF, and Schnabl B. Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. J Hepatol. 2014; 60(6):1259-67.
  41. Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, Loomba R. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015; 13(3):561-568.
  42. Chen P, Stärkel P, Turner JR, Ho SB, Schnabl B. Dysbiosis-induced intestinal inflammation activates TNFRI and mediates alcoholic liver disease in mice. Hepatology. 2015; 61(3):883-94.
  43. Fang S, Suh JM, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino A, Jacinto S, Lukasheva Y, Atkins AR, Khvat A, Schnabl B, Yu RT, Brenner DA, Coulter S, Liddle C, Schoonjans K, Olefsky JM, Saltiel AR, Downes M, Evans RM. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nature Medicine. 2015; 21(2):159-165.
  44. Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, Eckmann L, Dhungana S, Pathmasiri W, Sumner S, Westwater C, Brenner DA, Schnabl B. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J. 2015; 29(3):1043-55.
  45. Wang L, Llorente C, Hartmann P, Yang A, Chen P, Schnabl B. Methods to determine intestinal permeability and bacterial translocation during liver disease. J Immunol Methods. 2015; 421:44-53.
  46. Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, van Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, Schnabl B. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology. 2015;148(1):203-214.
  47. Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, Ix JH, Schnabl B, Sirlin CB, Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients with Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2015; 13(8):1513-1520.
  48. Chen P, Miyamoto Y, Mazagova M, Lee K, Eckmann L, Schnabl B. Microbiota protects mice against acute alcohol-induced liver injury. Alcohol Clin Exp Res. 2015; 39(12):2313-23.
  49. Schnabl B, Farshchi-Heydari S, Loomba R, Mattrey RF, Hoh CK, Sirlin CB, Brenner DA, Behling C, Vera DR. Staging of Fibrosis in Experimental Non-Alcoholic Steatohepatitis by Quantitative Molecular Imaging in Rat Models. Nuclear Medicine and Biology. 2016;43(2):179-87.
  50. Hartmann P, Seebauer CT, Mazagova M, Horvath A, Wang L, Llorente C, Varki NM, Brandl K, Ho SB, Schnabl B. Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. Am J Physiol Gastrointest Liver Physiol. 2016;310(5):G310-22.
  51. Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. Intestinal REG3 Lectins Protect Against Alcoholic Steatohepatitis by Reducing Mucosa-associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe. 2016; 19(2):227–239.
  52. Inamine T, Yang A, Wang L, Lee KC, Llorente C, Schnabl B. Genetic loss of immunoglobulin A does not influence development of alcoholic steatohepatitis in mice. Alcohol Clin Exp Res. 2016; 40(12):2604-2613
  53. Patel NS, Hooker J, Gonzalez M, Bhatt A, Nguyen P, Ramirez K, Richards L, Rizo E, Hernandez C, Kisseleva T, Schnabl B, Brenner D, Sirlin CB, Loomba R. Weight loss decreases magnetic resonance elastography estimated liver stiffness in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016; S1542-3565(16)30861-8.
  54. Eguchi A, Lazaro RG, Wang J, Kim J, Povero D, Willliams B, Ho SB, Stärkel P, Schnabl B, Ohno-Machado L, Tsukamoto H, Feldstein AE. Extracellular vesicles released by hepatocytes from gastric infusion model of ALD contain a miRNA barcode that can be detected in blood. Hepatology. 2017; 65(2):475-490.
  55. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE.Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017; 25(5):1054-1062.
  56. Yang A, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, KoyamaY, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen C, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017; 127(7):2829-2841.
  57. Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017, in press.

Reviews, Editorials and Conference Summaries, peer-reviewed

  1. Schnabl B, Scholten D, Brenner DA. What is the potential role of antifibrotic agents for the treatment of liver disease? Nat Clin Pract Gastroenterol Hepatol. 2008; 5(9):496-7.
  2. Schnabl B. Peroxisome proliferator-activated receptor-as emerging target in liver disease. Drug Dev Res. 2010; 71:106–111.
  3. Brenner DA, Seki E, Taura K, Kisseleva T, Deminicis S, Iwaisako K, Inokuchi S, Schnabl B, Oesterreicher CH, Paik YH, Miura K, Kodama Y. Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res. 2011; 41(7):683-6.
  4. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis - Crosstalk between the liver and gut. J Physiol. 2011; 590(Pt 3):447-58.
  5. Yan AW, Schnabl B. Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World J Hepatol. 2012;4(4):110-8.
  6. Hartmann P, Chen W, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol. 2012; 3:402.
  7. Brenner DA, Kisseleva T, Scholten D, Paik YH, Iwaisako K, Inokuchi S, Schnabl B, Seki E, De Minicis S, Oesterreicher C, Taura K. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair. 2012; 5 Suppl 1:S17.
  8. Schnabl B, Brenner DA. Fibroblast growth factor inducible 14 as potential target in patients with alcoholic hepatitis. Gut. 2013; 62(3):335-6.
  9. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013; 29(3):264-70.
  10. Schnabl B. Transplanting a fibrogenic microbiota. Hepatology. 2014, 59(5):1660-1.
  11. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014; 146(6):1513-24.
  12. Jalan R, Fernandez J, Weist R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot , Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Ginès P. Bacterial Infections in Cirrhosis. A position statement based on the EASL Special Conference. J Hepatol. 2014; 60(6):1310-24.
  13. Chen P, Schnabl B. Host-microbiome interactions in alcoholic liver disease. Gut and Liver. 2014, 8(3):237-241.
  14. Schnabl B. The Microbiome and the Liver. Gastroenterol Hepatol (N Y). 2014; 10(8):519-21.
  15. Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: The gut microbiome and liver crosstalk. Alcohol Clin Exp Res. 2015; 39(5):763-75.
  16. Llorente C, Schnabl B. The gut microbiota and liver disease. Cell and Mol Gastroenterol and Hepatol. 2015; 1(3):275–284.
  17. Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease? Expert Rev Gastroenterol Hepatol. 2015; 9(8):1069-76.
  18. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015; 63(5):1272-84.
  19. Brenner DA, Paik YH, Schnabl B. Role of gut microbiota in liver disease. J Clin Gastroenterol. 2015; 49 Suppl 1:S25-7.
  20. Ho SB, Matheny M, Schnabl B. Changes in hospital admissions and mortality for complications of cirrhosis: implications for clinicians and health systems. Gut and Liver. 2016; 10(1):8-9.
  21. Nakamoto N, Schnabl B. Does the intestinal microbiota explain differences in the epidemiology of liver disease between East and West? Inflamm Intest Dis. 2016; 1(1):3-8.
  22. Schnabl B. Liver Capsule: Mechanisms of Alcoholic Hepatitis. Hepatology. 2016; 64(1):276.
  23. Fuchs M, Schnabl B. Editors' Introduction to the NAFLD and NASH Special Issue. Dig Dis Sci. 2016; 61(5):1211-3.
  24. Arroyo V, Moreau R, Kamath PS, Jalan R, Gines P, Nevens F, Fernandez J, To U, Garcia-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. Nature Reviews Disease Primers. 2016; 2:16041.
  25. Chen P, Miyamoto Y, Mazagova M, Lee K, Eckmann L, Schnabl B. Microbiota and alcoholic liver disease. Alcohol Clin Exp Res. 2016; 40(8):1791-2.
  26. Llorente C, Schnabl B. Fast-track clearance of bacteria from the liver. Cell Host Microbe. 2016; 20(1):1-2
  27. Stärkel P, Schnabl B. Bidirectional communication between liver and gut during alcoholic liver disease. Semin Liver Dis. 2016; 36(4):331-339.
  28. Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and non-alcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016; 311(6):G1018-G1036.
  29. Brandl K, Schnabl B. The intestinal microbiota and NASH. Curr Opin Gastroenterol. 2017; 33(3):128-133.
  30. Boule LA, Ju C, Agudelo M, Parira T, Cannon A, Davis B, Eby J, Cresci G, Samuelson DR, Shukla P, Alrefai WA, Sureshchandra S, Pandey SC, Schnabl B, Curtis BJ, Wyatt TA, Choudhry MA, Kovacs EJ. Summary of the 2016 Alcohol and Immunology Research Interest Group (AIRIG) meeting. Alcohol. 2017, accepted.
  31. Hochrath K, Schnabl B. Check your microbiota when taking the drug. Hepatology. 2017, accepted.
  32. Hendrikx T, Schnabl B. Lamin deficiency in the liver sets the stage for NASH development in men. Cell and Mol Gastroenterol and Hepatol. 2017, accepted.

Book Chapters

  1. Schnabl B. Metagenomic applications and the potential for understanding chronic liver disease. In Nelson KE, Editor. Metagenomics of the Human Body. Springer; 2010: 277-96.
  2. Brandl K, Schnabl B. Liver Disease: Interactions with the Intestinal Microbiota. In Luigi Nibali and Brian Henderson, Editors. The human microbiota and chronic disease – dysbioses as a cause of human pathology. Wiley Blackwell; 2016.
  3. Hartmann P, Schnabl B. Translocation of bacteria and bacterial products from the intestinal lumen in cirrhosis. Role of microbiota, intestinal mucosal integrity and local immune function. In Arroyo V, Editor. Acute-on-Chronic Liver Failure. 2016